Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the operating margin high or low?
The operating margin of -1776.32% is 20% above its 3-year average of -2217.46%, near the high end of its 3-year range (-8956.38%–0.00%).
70.84% above its 12-month average of -6092.11%.
Reported quarterly operating margin; no daily interpolation. Q2 FY2026 (2026-06-30): -8956.38%.
OPERATING MARGIN
-1776.32%
OPERATING MARGIN AVG TTM
-6092.11%
OPERATING MARGIN AVG 3Y
-2388.03%
OPERATING MARGIN AVG 5Y
N/A
OPERATING MARGIN AVG 10Y
N/A
OPERATING MARGIN AVG 15Y
N/A
OPERATING MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+70.84%
CURRENT VS 3Y AVG
+25.62%
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.00%
median of 494 covered companies
CURRENT VS SECTOR MEDIAN
N/A
vs the sector median at left
Alumis Inc.
Market Cap
$844.28M
Operating Margin
-1776.32%
TTM Avg
-6092.11%
3Y Avg
-2388.03%
5Y Avg
N/A
Market Cap
$837.43M
Operating Margin
-7.86%
TTM Avg
-9.22%
3Y Avg
-47.88%
5Y Avg
-486.53%
Market Cap
$852.55M
Operating Margin
-69.75%
TTM Avg
-70.49%
3Y Avg
-9306.05%
5Y Avg
-9306.05%
Market Cap
$856.30M
Operating Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$867.60M
Operating Margin
-43.83%
TTM Avg
-75.55%
3Y Avg
-37.77%
5Y Avg
-25.18%
Market Cap
$819.44M
Operating Margin
9.86%
TTM Avg
12.61%
3Y Avg
-6.26%
5Y Avg
-239.99%
Market Cap
$786.48M
Operating Margin
-21.60%
TTM Avg
-15.14%
3Y Avg
-11.45%
5Y Avg
-3.99%
| NAME | MARKET CAP | OPERATING MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Alumis Inc. (ALMS) | $844.28M | -1776.32% | -6092.11% | -2388.03% | N/A |
| Ardelyx, Inc. (ARDX)vs › | $837.43M | -7.86% | -9.22% | -47.88% | -486.53% |
| Beta Bionics, Inc. (BBNX)vs › | $852.55M | -69.75% | -70.49% | -9306.05% | -9306.05% |
| Jade Biosciences, Inc. (JBIO)vs › | $856.30M | 0.00% | 0.00% | 0.00% | 0.00% |
| Apnimed, Inc. (APMD)vs › | $866.15M | N/A | N/A | N/A | N/A |
| Monte Rosa Therapeutics, Inc. (GLUE)vs › | $867.60M | -43.83% | -75.55% | -37.77% | -25.18% |
| Gyre Therapeutics, Inc. (GYRE)vs › | $819.44M | 9.86% | 12.61% | -6.26% | -239.99% |
| InMode Ltd. (INMD)vs › | $812.20M | 18.47% | 25.77% | 33.72% | 36.17% |
| Cytek Biosciences, Inc. (CTKB)vs › | $786.48M | -21.60% | -15.14% | -11.45% | -3.99% |
| Corvus Pharmaceuticals, Inc. (CRVS)vs › | $903.13M | 0.00% | 0.00% | 0.00% | 0.00% |
Gross Margin
88.2%
Operating Margin
-1776.3%
Operating Margin = Operating Income / Revenue
Operating margin is the percentage of revenue remaining after operating expenses, reflecting operating efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | OPERATING MARGIN |
|---|---|
| 2026-06-30 | -8956.38% |
| 2026-03-31 | -5652.44% |
| 2025-12-31 | -4999.74% |
| 2025-09-30 | -5580.45% |
| 2025-06-30 | -5271.53% |
| 2025-03-31 | -583.86% |
| 2024-12-31 | 0.00% |
| 2024-09-30 | 0.00% |
| 2024-06-30 | 0.00% |
| 2024-03-31 | 0.00% |
| 2023-12-31 | 0.00% |
| 2023-09-30 | 0.00% |
| 2023-06-30 | 0.00% |
| 2023-03-31 | 0.00% |
